TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33356015

Group type: EXPERIMENTAL
Intervention: Afternoon exercise training (3.00-6.00 p.m., N = 20)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Morning exercise training (8.00-10.00 a.m., N = 12)
Number of subjects: 32
Study: 33356019

Group type: EXPERIMENTAL
Intervention: Single oral 100-mg glasdegib dose under fasted conditions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched controls with normal hepatic function
Number of subjects: 0
Study: 33356355

Group type: EXPERIMENTAL
Intervention: Previous myocardial infarction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33356383

Group type: EXPERIMENTAL
Intervention: Bashir Endovascular Catheter (BEC)
Number of subjects: 9
Study: 33356392

Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 13
Study: 33356398

Group type: COMPARATOR
Intervention: Systolic BP <120 mm Hg
Number of subjects: 1738

Group type: EXPERIMENTAL
Intervention: Systolic BP 120 to 140 mm Hg
Number of subjects: 1738

Group type: EXPERIMENTAL
Intervention: Systolic BP 140 to 160 mm Hg
Number of subjects: 1738

Group type: EXPERIMENTAL
Intervention: Systolic BP ≥160 mm Hg
Number of subjects: 1738
Study: 33356406

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator (ICD) therapy
Number of subjects: 4296

Group type: EXPERIMENTAL
Intervention: Delayed high-rate detection and single-zone programming
Number of subjects: 4296
Study: 33356665

Group type: EXPERIMENTAL
Intervention: Availability of POC culture
Number of subjects: 1545

Group type: COMPARATOR
Intervention: No availability of POC culture
Number of subjects: 1545
Study: 33357452

Group type: EXPERIMENTAL
Intervention: Immunogenic chemotherapy combined with checkpoint blockade
Number of subjects: 0

Group type: COMPARATOR
Intervention: Checkpoint blockade alone
Number of subjects: 0
Study: 33357481

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33358103

Group type: EXPERIMENTAL
Intervention: Endovascular treatment with aortic endoprosthesis
Number of subjects: 91

Group type: COMPARATOR
Intervention: Deployment in zone 0-1
Number of subjects: 91

Group type: COMPARATOR
Intervention: Branched or fenestrated endograft
Number of subjects: 91

Group type: COMPARATOR
Intervention: Proximal endoprosthesis diameter ≥ 40 mm
Number of subjects: 91

Group type: COMPARATOR
Intervention: Urgent procedure
Number of subjects: 91
Study: 33358451

Group type: EXPERIMENTAL
Intervention: Aldosterone antagonists (spironolactone, eplerenone) added to ACE inhibitors (ACEi) or angiotensin II receptor blockers (ARBs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonsteroidal MR blockers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Finerenone added to treatment in patients with type 2 diabetes mellitus and CKD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium glucose type 2 cotransporter inhibitors (SGLT2i)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triple combination of ACEi or ARBs, SGLT2i, and aldosterone antagonist
Number of subjects: 0
Study: 33358484

Group type: EXPERIMENTAL
Intervention: Biomarker testing for EGFR, ALK, ROS1, BRAF, KRAS, MET, TP53, RET, HER2, and PD-L1 expression
Number of subjects: 3717

Group type: EXPERIMENTAL
Intervention: Testing for druggable EGFR mutations
Number of subjects: 3717

Group type: EXPERIMENTAL
Intervention: Testing for druggable ALK alterations
Number of subjects: 3717

Group type: EXPERIMENTAL
Intervention: Testing for KRAS alterations
Number of subjects: 3717

Group type: EXPERIMENTAL
Intervention: Testing for TP53 alterations
Number of subjects: 3717

Group type: EXPERIMENTAL
Intervention: Testing for EGFR alterations
Number of subjects: 3717

Group type: EXPERIMENTAL
Intervention: Testing for PD-L1 expression
Number of subjects: 3717

Group type: EXPERIMENTAL
Intervention: Testing methods used
Number of subjects: 3717
Study: 33358660

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33358713

Group type: EXPERIMENTAL
Intervention: Alternate Day Fasting (ADF) - 500 kcal fast day alternated with ad libitum intake feast day for 12 weeks
Number of subjects: 75
Study: 33358716

Group type: EXPERIMENTAL
Intervention: Skin carotenoids status (SCS)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Plasma carotenoids
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Dietary carotenoids
Number of subjects: 103
Study: 33359234

Group type: EXPERIMENTAL
Intervention: Abnormal liver tests on admission
Number of subjects: 1611
Study: 33359373

Group type: EXPERIMENTAL
Intervention: Ideal pain trajectory (rapid and sustained pain relief)
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Non-ideal pain trajectory (late, transient, or no pain relief)
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Persistent post-surgical pain (PPSP)
Number of subjects: 308

Group type: COMPARATOR
Intervention: Non-ideal pain trajectories
Number of subjects: 308
Study: 33359404

Group type: EXPERIMENTAL
Intervention: Avelumab 10 mg/kg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard second-line doublet chemotherapy plus a targeted agent
Number of subjects: 100
Study: 33359443

Group type: EXPERIMENTAL
Intervention: Severe recurrent wheeze (SRW)
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Severe asthma (SA)
Number of subjects: 338
Study: 33360365

Group type: EXPERIMENTAL
Intervention: Mobile-enhanced family-focused therapy (FFT) with a mobile app (12 sessions in 18 weeks)
Number of subjects: 22
Study: 33360855

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 1567
Study: 33361170

Group type: EXPERIMENTAL
Intervention: Personalised breast cancer screening intervention
Number of subjects: 385
Study: 33361275

Group type: EXPERIMENTAL
Intervention: Virtual simulation with Sim&Size software
Number of subjects: 186

Group type: COMPARATOR
Intervention: Conventional sizing
Number of subjects: 186
Study: 33361296

Group type: EXPERIMENTAL
Intervention: Fluconazole (dosage not specified) as prophylaxis or treatment
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Fluconazole (dosage not specified)
Number of subjects: 33
Study: 33361303

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP) administered in standard 3-day courses at 4- to 8-week intervals from the second trimester until delivery.
Number of subjects: 467
Study: 33361353

Group type: EXPERIMENTAL
Intervention: NYHA I
Number of subjects: 188
Study: 33362277

Group type: EXPERIMENTAL
Intervention: Endo-CABG
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 180
Study: 33362485

Group type: EXPERIMENTAL
Intervention: Ketamine treatment for AUD, specific dosage and duration not mentioned.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 33362497

Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (sham stimulation)
Number of subjects: 0
Study: 33362687

Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mirror Therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study: 33362722

Group type: EXPERIMENTAL
Intervention: Ipilimumab and nivolumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anti-PD-1 (pembrolizumab)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nivolumab and ipilimumab
Number of subjects: 0
Study: 33362883

Group type: EXPERIMENTAL
Intervention: Intervention schools implementing the adapted life orientation curriculum with scripted lesson plans
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 0
Study: 33362896

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0
Study: 33363071

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) and Adalimumab (ADA)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Healthy controls (siblings of JIA patients)
Number of subjects: 63
Study: 33363453

Group type: EXPERIMENTAL
Intervention: Remote and wireless programming system for SCS devices
Number of subjects: 16
Study: 33364332

Group type: EXPERIMENTAL
Intervention: Common OSA screening tools
Number of subjects: 0
Study: 33364733

Group type: EXPERIMENTAL
Intervention: Confusion Assessment Method (CAM)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nursing Delirium Screening Scale (nu-DESC)
Number of subjects: 60
Study: 33364840

Group type: EXPERIMENTAL
Intervention: Maintenance olaparib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33365012

Group type: EXPERIMENTAL
Intervention: Exercise and diet interventions
Number of subjects: 24
Study: 33365220

Group type: EXPERIMENTAL
Intervention: Icosapent Ethyl (IPE, Vascepa®)
Number of subjects: 1
Study: 33365325

Group type: EXPERIMENTAL
Intervention: Higher protein-lower glycemic index diet (HPLG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional moderate protein-moderate glycemic index diet (MPMG)
Number of subjects: 0
Study: 33367114

Group type: EXPERIMENTAL
Intervention: COPE plus usual HCBS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 0
Study: 33367731

Group type: EXPERIMENTAL
Intervention: Fostamatinib (R406)
Number of subjects: 0
Study: 33367735

Group type: EXPERIMENTAL
Intervention: Lactobacillus crispatus or Lactobacillus gasseri dominance in black women (n=12, 27%)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Vaginal microbial communities
Number of subjects: 44
Study: 33367811

Group type: EXPERIMENTAL
Intervention: Fasting plasma glucose (FPG) variability measures (coefficient of variation (CV) and average real variability (ARV)) in ACCORD and VADT.
Number of subjects: 12042

Group type: EXPERIMENTAL
Intervention: Fasting plasma glucose (FPG) variability measures (CV and ARV) in both trials.
Number of subjects: 12042
Study: 33367837

Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors
Number of subjects: 0
Study: 33367918

Group type: EXPERIMENTAL
Intervention: nOPV2-c1 (S2/cre5/S15domV/rec1/hifi3)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: nOPV2-c2 (S2/S15domV/CpG40)
Number of subjects: 30
Study: 33367975

Group type: EXPERIMENTAL
Intervention: Darunavir/Ritonavir (DRV/r)
Number of subjects: 46
Study: 33368056

Group type: EXPERIMENTAL
Intervention: Computer-aided diagnosis system (CADx) using high-definition white-light (HDWL) images
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Computer-aided diagnosis system (CADx) using blue-light imaging (BLI) images
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Computer-aided diagnosis system (CADx) using multimodal imaging (HDWL and BLI)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Optical diagnosis by expert endoscopists
Number of subjects: 60

Group type: COMPARATOR
Intervention: Optical diagnosis by novice endoscopists
Number of subjects: 60

Group type: COMPARATOR
Intervention: BLI Adenoma Serrated International Classification (BASIC)
Number of subjects: 60
Study: 33368142

Group type: EXPERIMENTAL
Intervention: Antenatal corticosteroids
Number of subjects: 11272
Study: 33368493

Group type: EXPERIMENTAL
Intervention: Periodontal inflammation (PI)
Number of subjects: 770

Group type: EXPERIMENTAL
Intervention: Renal function
Number of subjects: 770
Study: 33368557

Group type: EXPERIMENTAL
Intervention: Pregnant women with type 2 diabetes
Number of subjects: 178

Group type: COMPARATOR
Intervention: Pregnant women without diabetes
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Pregnant women with type 2 diabetes with anxiety and/or depression symptoms
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Pregnant women with type 2 diabetes without anxiety and/or depression symptoms
Number of subjects: 178
Study: 33368569

Group type: EXPERIMENTAL
Intervention: Erythrocytapheresis (n = 71)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Phlebotomy (n = 54)
Number of subjects: 125
Study: 33368935

Group type: EXPERIMENTAL
Intervention: Dapagliflozin treatment
Number of subjects: 0
Study: 33369212

Group type: EXPERIMENTAL
Intervention: ST Genesia (STG-ThromboScreen and STG-DrugScreen reagents)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rivaroxaban and apixaban
Number of subjects: 0

Group type: COMPARATOR
Intervention: ST Genesia (STG-ThromboScreen)
Number of subjects: 0
Study: 33369356

Group type: EXPERIMENTAL
Intervention: Pregnant women with epilepsy during epoch 1 (pregnancy)
Number of subjects: 351

Group type: COMPARATOR
Intervention: Nonpregnant controls with epilepsy during epoch 1
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Pregnant women
Number of subjects: 351

Group type: COMPARATOR
Intervention: Nonpregnant controls
Number of subjects: 351
Study: 33369570

Group type: EXPERIMENTAL
Intervention: Monitored inhaled corticosteroid treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Assessment of adherence and FeNO response
Number of subjects: 0
Study: 33369580

Group type: EXPERIMENTAL
Intervention: Niraparib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Olaparib in combination with bevacizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PARP inhibitors (PARPi)
Number of subjects: 0
Study: 33369581

Group type: EXPERIMENTAL
Intervention: New drugs for HER2-positive breast cancer (specific drugs not mentioned)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunotherapy and CDK4/6 inhibitors
Number of subjects: 0
Study: 33369965

Group type: EXPERIMENTAL
Intervention: Cough Stress Test (CST)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Pyridium Pad Test
Number of subjects: 84

Group type: COMPARATOR
Intervention: Urodynamics (UDS)
Number of subjects: 84
Study: 33369988

Group type: EXPERIMENTAL
Intervention: Extensive multimodal strategy (biopsy forceps, cytology brush, aspirating needle, triple needle cytology brush, needle-tipped cytology brush, core biopsy system, and bronchoalveolar lavage)
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Rapid On-Site Evaluation (ROSE)
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Biopsy forceps
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Aspirating needle
Number of subjects: 416

Group type: COMPARATOR
Intervention: Restricted tool strategy (only biopsy forceps, standard cytology brush, and/or bronchoalveolar lavage)
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Extensive tool strategy
Number of subjects: 416

Group type: COMPARATOR
Intervention: Restricted tool strategy
Number of subjects: 416
Study: 33370024

Group type: EXPERIMENTAL
Intervention: Chemoradiation
Number of subjects: 294

Group type: COMPARATOR
Intervention: Chemotherapy only
Number of subjects: 294
Study: 33370479

Group type: EXPERIMENTAL
Intervention: Patients with PK deficiency (n = 122)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Regularly transfused patients (n = 65)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Never transfused patients with PK deficiency
Number of subjects: 122

Group type: COMPARATOR
Intervention: Matched population (n = 1220)
Number of subjects: 122
Study: 33370721

Group type: EXPERIMENTAL
Intervention: Random messaging arm (text messaging intervention)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Reinforcement learning arm (text messaging intervention)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 229
Study: 33371015

Group type: EXPERIMENTAL
Intervention: Visual Inspection after application of acetic acid (VIA)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Portable magnification device (Gynocular) based on the Swede score assessment
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: High-risk subtypes of human papillomavirus (HR-HPV, GeneXpert)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Combination of tests (VIA, Gynocular, HR-HPV)
Number of subjects: 450
Study: 33371021

Group type: EXPERIMENTAL
Intervention: Confirmed IBD cases
Number of subjects: 86

Group type: COMPARATOR
Intervention: Non-IBD controls (sibling or second-degree relative, randomly selected individual from the same neighborhood)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: IBD cases
Number of subjects: 86

Group type: COMPARATOR
Intervention: Non-IBD controls
Number of subjects: 86
Study: 33371020

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-of-care (SOC) therapy
Number of subjects: 0
Study: 33371033

Group type: EXPERIMENTAL
Intervention: Triple antithrombotic therapy (TAT)
Number of subjects: 598

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT)
Number of subjects: 598

Group type: EXPERIMENTAL
Intervention: Dual antithrombotic therapy (DAT)
Number of subjects: 598

Group type: EXPERIMENTAL
Intervention: Major bleeding event
Number of subjects: 598

Group type: EXPERIMENTAL
Intervention: Malignancy
Number of subjects: 598
Study: 33371044

Group type: EXPERIMENTAL
Intervention: DPP4 inhibitor
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Thiazolidinedione
Number of subjects: 520
Study: 33371048

Group type: EXPERIMENTAL
Intervention: Financial incentives
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nurse coaching
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33371779

Group type: EXPERIMENTAL
Intervention: 1% IQP-0528 gel (10 mL rectal dose)
Number of subjects: 7
Study: 33372102

Group type: EXPERIMENTAL
Intervention: Clinical governance programme
Number of subjects: 5000
Study: 33372414

Group type: EXPERIMENTAL
Intervention: Low gland formation and low neutrophil infiltration
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: High gland formation and high neutrophils
Number of subjects: 50
Study: 33372647

Group type: EXPERIMENTAL
Intervention: ANZANSI (family economic empowerment + multiple family groups)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control arm (no intervention)
Number of subjects: 100
Study: 33373024

Group type: EXPERIMENTAL
Intervention: Endovascular treatment (ET) in OAC patients
Number of subjects: 1306
Study: 33373359

Group type: EXPERIMENTAL
Intervention: Aortic stiffness measured by pulse wave velocity (PWV)
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: Baseline aortic stiffness
Number of subjects: 542
Study: 33373732

Group type: EXPERIMENTAL
Intervention: Aminoglycoside resistance testing
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Identification of rmtB gene
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Plasmid analysis
Number of subjects: 100
Study: 33373868

Group type: EXPERIMENTAL
Intervention: Preoperative pembrolizumab combined with concurrent chemoradiotherapy (PPCT)
Number of subjects: 20
Study: 33373873

Group type: EXPERIMENTAL
Intervention: Epidermal growth factor receptor (EGFR) inhibition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined inhibition of EGFR and TNF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Drugs inhibiting TNF
Number of subjects: 0
Study: 33374003

Group type: EXPERIMENTAL
Intervention: Anti-dsDNA IgG2
Number of subjects: 1052

Group type: EXPERIMENTAL
Intervention: Anti-C1q IgG2
Number of subjects: 1052

Group type: EXPERIMENTAL
Intervention: Anti-ENO1 IgG2
Number of subjects: 1052

Group type: EXPERIMENTAL
Intervention: Anti-H2A IgG2
Number of subjects: 1052

Group type: EXPERIMENTAL
Intervention: SLEDAI values correlation
Number of subjects: 1052

Group type: EXPERIMENTAL
Intervention: Nephritogenic IgG2 antibodies
Number of subjects: 1052
Study: 33374007

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33376102

Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 1803

Group type: COMPARATOR
Intervention: Placebo (REPRISE)
Number of subjects: 1803
Study: 33376109

Group type: EXPERIMENTAL
Intervention: Sirolimus treatment for 6 months at plasma concentration levels of 5-8 µg/L
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Sirolimus treatment for 6 months
Number of subjects: 4
Study: 33376169

Group type: EXPERIMENTAL
Intervention: High CRP level (>10 mg/L) at discharge
Number of subjects: 2618

Group type: COMPARATOR
Intervention: Low CRP level (≤10 mg/L) at discharge
Number of subjects: 2618
Study: 33376179

Group type: EXPERIMENTAL
Intervention: Combination of clinical, functional and circulating biomarkers
Number of subjects: 0
Study: 33376181

Group type: EXPERIMENTAL
Intervention: Medical cannabis use
Number of subjects: 250
Study: 33376186

Group type: EXPERIMENTAL
Intervention: Masculinising testosterone treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Coronary CT angiography
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Upper body muscle strength and power measurement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Questionnaires for aggression and quality of life
Number of subjects: 0
Study: 33376319

Group type: EXPERIMENTAL
Intervention: Daily step count measurement using an activity monitor over 14 consecutive days.
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Assessment of activity time at ≥3 METs (moderate-to-vigorous) and ≥2 METs (light-to-vigorous).
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Correlation analysis between physical activity (PA) and patient characteristics.
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Subjective reports of time spent in activities requiring ≥2 METs.
Number of subjects: 417
Study: 33377125

Group type: EXPERIMENTAL
Intervention: Plasma dihydroceramides in triglyceride-rich very-low-density lipoprotein (VLDL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Expression of sphingolipid synthesis enzymes
Number of subjects: 0
Study: 33377129

Group type: EXPERIMENTAL
Intervention: Patient-powered arm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physician-reported arm
Number of subjects: 0
Study: 33377134

Group type: EXPERIMENTAL
Intervention: PD-1 x CTLA-4 bispecific DART molecule (MGD019)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination immunotherapy with antibodies directed against PD-1 and CTLA-4
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single agents (PD-1 or CTLA-4 antibodies)
Number of subjects: 0
Study: 33377138

Group type: EXPERIMENTAL
Intervention: Aliviado Dementia Care-Hospice Edition
Number of subjects: 83
Study: 33377328

Group type: EXPERIMENTAL
Intervention: RDN with DENEX™ system
Number of subjects: 16
Study: 33378372

Group type: EXPERIMENTAL
Intervention: Safe Childbirth Checklist (SCC) and systems-focused mentorship
Number of subjects: 256
Study: 33378384

Group type: EXPERIMENTAL
Intervention: Low-dose ICS
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: High-dose fluticasone propionate
Number of subjects: 55

Group type: COMPARATOR
Intervention: High-dose budesonide
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Both low and high-dose ICS
Number of subjects: 55